vTv Therapeutics Inc expected to post a loss of $1.04 a share - Earnings Preview

vTv Therapeutics

07/08/2026 15:09

vTv Therapeutics Inc VTVT.OQ VTVT.O is expected to  show a rise in quarterly revenue when it reports  results on November 4 (estimated) for the period ending September 30 2026
The High Point North Carolina-based  company is expected to report revenue of $300 thousand, according to the mean estimate from 3 analysts, based on LSEG data.
​LSEG's mean analyst estimate for vTv Therapeutics Inc is for a loss of $1.04 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts had risen by about 1.4% in the last three months. ​
Wall Street's median 12-month price target for vTv Therapeutics Inc is $57.00, about 64.7% above its last closing price of $34.61
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2026
-0.86
-0.99
-1.05
Missed
-6.1
Mar. 31 2026
0.06
-0.09
1.94
Beat
2,142.1
Dec. 31 2025
-1.04
-1.09
-0.58
Beat
46.7​
Sep. 30 2025
-0.98
-0.98
-1.08
Missed
-10.2
​​Jun. 30 2025
-0.82
-0.82
-0.92
Missed
-11.5
Mar. 31 2025
-0.81
-0.81
-0.77
Beat
5.5​
Dec. 31 2024
-0.87
-0.87
-0.55
Beat
36.8
This summary was machine generated August 7 at 14:09 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)